logo
From Cork to Maidenhead: An Irish nurse's story

From Cork to Maidenhead: An Irish nurse's story

Yahoo8 hours ago

A nurse who moved from Ireland to Berkshire in 1948 at the age of 19 to join the newly created National Health Service (NHS) was a "pioneer", her daughter has said.
Nora McCarthy was one of thousands of Irish women recruited to train and work in British hospitals after the end of World War Two.
Janie Davies said her mother, who died last year aged 95, "absolutely loved" her job as a nurse.
Speaking to Radio Berkshire ahead the 77th anniversary of the NHS on 5 July, she said her mother told her it had been "very strict" in the early days.
The NHS took control of 480,000 hospital beds in England and Wales in 1948 but it was short of 48,000 nurses so an active recruitment drive was launched in Ireland.
At the time, nurse training opportunities in Ireland were limited and expensive, making the chance to train for free in British hospitals with live-in accommodation highly attractive.
By the 1960s there were about 30,000 Irish nurses working in the NHS.
Ms Davies said her mother saw an advert and decided she wanted to help.
Nora first spent a year working at a hospital in Highgate, London, on an orthopaedic ward before an outbreak of tuberculosis (TB), she said.
"About summertime 1949, mum and her friend wanted to apply for a job in Maidenhead," she said.
"I think working a year on the TB ward was just getting to them, they were seeing a lot of death."
Nora spoke fondly of her time in the NHS, said Ms Davies, adding that during the early years she had said it was "very strict" but there was "a lot of camaraderie too".
She said her mother had told her of dances at the local church hall which the off-duty nurses would attend and where Nora met her future husband.
Ms Davies' daughter Ciara has retraced Nora's journey from Cork to working at Maidenhead General Hospital in Berkshire, as part of her university dissertation.
She said: "I started in Ireland, we went to the original green rooms in O'Donovan's where the [nursing] interviews had taken place.
"Then to where she caught the bus from in Cork. We saw a little bit of Maidenhead but the original building for Maidenhead General Hospital was no longer there.
"There were some surprises about her life that I didn't know, such as learning about tuberculosis and what her life was like on the TB ward."
Nora worked as an NHS nurse for 50 years, retiring at the age of 69.
Her story has been featured in a book, titled Irish Nurses in the NHS - An Oral History, which explores the life experiences of the Irish migrant nurses.
Its co-author Prof Louise Ryan said the NHS described how it was "actively recruiting" in Ireland, with advertisements in national and local papers.
NHS recruiters travelled throughout the country and carried out interviews with young women in local hotels.
Prof Ryan said: "Their travel was paid, they earned a salary while they trained - plus they got accommodation in the nurses home.
"If you can image parents waving their children off on this mammoth journey across the sea to England – knowing there was secure accommodation was very reassuring – they were very well looked after."
You can follow BBC Berkshire on Facebook, X (Twitter), or Instagram.
Nurses 'proud' to celebrate 40 years of NHS care
Nursery nurse congratulated for 45 years of service
NHS nurses and healthcare staff offered 5.5% pay rise
'NHS needs fewer managers, more nurses'
NHS
Irish Nurses in the NHS - An Oral History

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight
Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight

Yahoo

timean hour ago

  • Yahoo

Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the . Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief executive's reaffirmation that the company will continue to offer cheaper compounded versions of GLP-1 weight-loss drugs, following its terminated partnership with Novo Nordisk. According to Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum, he was upset that Novo was feeling the pressure and was not comfortable. A nurse in a telehealth platform talking with a patient on video call for consultation. 'But ultimately, I think us holding strong to fighting on behalf of customers is just who we are. There's just no way in hell we're going to cave on that, no matter who the pharma company is or what the partnership looks like,' he noted. Novo Nordisk terminated its partnership with Hims & Hers Health, Inc. (NYSE:HIMS), alleging the latter of failing to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of 'personalization.' Novo Nordisk also claimed that Hims & Hers Health, Inc. (NYSE:HIMS) was disseminating deceptive marketing that put patient safety at risk. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.

Allegheny Health Network and Cigna Healthcare announce 3-year contract agreement
Allegheny Health Network and Cigna Healthcare announce 3-year contract agreement

CBS News

timean hour ago

  • CBS News

Allegheny Health Network and Cigna Healthcare announce 3-year contract agreement

On Friday, Allegheny Health Network and Cigna Healthcare announced a new, three-year contract agreement that will ensure those on Cigna insurance will continue to have access to AHN facilities. "This contract is fantastic news for the more than 20,000 Cigna members in this region who rely on AHN for their care," said AHN President Mark Sevco. "It ensures continued, in-network access to AHN's expert clinicians, and to the exceptional-quality, high-value care that their members and our patients expect and deserve." Beneficiaries will continue to have in-network access to AHN's clinical programs, 14 hospitals, and the doctors and specialists employed by AHN. Patients who have appointments in the next week will still be able to keep them, and the new contract goes through June 30, 2028. Those covered by Cigna insurance who may have questions about the new contract can call the Cigna customer service line at 1-800-997-1654.

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Yahoo

time2 hours ago

  • Yahoo

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store